Belli Acne Control Spot Treatment

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: Belli Acne Control Spot Treatment
Generic name: SULFUR
Manufacturer: BODY HALO LLC
Product type: HUMAN OTC DRUG
SPL set ID: da979b69-1e4c-4e2b-82c3-0f155e978652
SPL ID: 2cdcb7de-ce78-3d94-e063-6394a90a8bec
Version: 8
Effective date: 2025-01-29
Source export date: 2026-09-28
Source partition: 12
Source file: https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-09-28/663999d0fe1757c1e2cd13a4799d76d875f663e0bc57701092264ebe7febfc18/drug-label-0012-of-0014.json.zip
Source manifest SHA-256: cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run: 20260929T050834Z
Imported at: 2026-09-29 06:25:27

Harmonized routes table
Harmonized routes
TOPICAL

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 11 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
application number		M006	openfda.application_number
brand name		Belli Acne Control Spot Treatment	openfda.brand_name
generic name		SULFUR	openfda.generic_name
manufacturer name		BODY HALO LLC	openfda.manufacturer_name
ndc	package	42281-001-00	openfda.package_ndc
ndc	product	42281-001	openfda.product_ndc
ndc11	package	42281000100	derived:openfda.package_ndc
rxcui		199632	openfda.rxcui
spl id		2cdcb7de-ce78-3d94-e063-6394a90a8bec	id
spl set id		da979b69-1e4c-4e2b-82c3-0f155e978652	set_id
unii		70FD1KFU70	openfda.unii

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

Warnings For external use only. Using other topical acne medications at the same time or immediately following use of this product may increase dryness or irritation of the skin. If this occurs, only one medication should be used unless directed by a doctor. Do not get into eyes. If excessive skin irritation develops or increases, discontinue use and consult a doctor.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.